We recently completed a MARA Rating for a treatment for a kidney disease that can progress to kidney failure over time.

The phase 3 trial answered one question clearly: does this treatment reduce protein in the urine? It does. By 50%, compared to placebo.

Payers ask a different question: does that reduction translate into preserved kidney function and better outcomes for patients — at an acceptable cost?

That question was not answered. The FDA noted that long-term clinical benefit has not been established. The estimated cost per outcome gained was $894,000.

Two questions. One answered. One not.

Read the full MARA Rating here: https://mararating.com/report/sibeprenlimab-szsi-voyxact-for-reducing-proteinuria-in-adults-with-primary-iga-nephropathy-as-of-february-2026/